Suppr超能文献

一名肺腺癌患者出现纳武单抗诱导的垂体炎、继发性肾上腺功能不全和破坏性甲状腺炎

Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma.

作者信息

Mishima Yuka, Fukaishi Takahiro, Inase Naohiko, Isogai Susumu

机构信息

Respiratory Medicine, Ome Municipal General Hospital, Japan.

Endocrinology and Metabolism, Ome Municipal General Hospital, Japan.

出版信息

Intern Med. 2019 Mar 1;58(5):693-697. doi: 10.2169/internalmedicine.1268-18. Epub 2018 Nov 19.

Abstract

Nivolumab-induced multiple organ immune-related adverse events (irAEs) have been described in some case reports. The symptoms of endocrinological irAEs are especially nonspecific. A 63-year-old man with a postoperative recurrence of pulmonary adenocarcinoma who was treated with nivolumab presented fever, anorexia and fatigue after the 7th cycle. He underwent a rapid adrenocorticotrophic hormone test, four-hormone tolerance test and thyroid gland scintigraphy. The results were consistent with destructive thyroiditis, hypophysitis and secondary adrenal insufficiency. Nivolumab was restarted following glucocorticoid and thyroid hormone replacement treatment. When a patient presents nonspecific symptoms, the possibility of endocrinological irAEs should be considered as it may enable their early detection.

摘要

一些病例报告中描述了纳武单抗诱导的多器官免疫相关不良事件(irAEs)。内分泌irAEs的症状尤其不具有特异性。一名63岁的肺腺癌术后复发患者接受纳武单抗治疗,在第7个周期后出现发热、厌食和疲劳。他接受了促肾上腺皮质激素快速试验、四项激素耐量试验和甲状腺闪烁扫描。结果与破坏性甲状腺炎、垂体炎和继发性肾上腺功能不全一致。在糖皮质激素和甲状腺激素替代治疗后重新开始使用纳武单抗。当患者出现非特异性症状时,应考虑内分泌irAEs的可能性,因为这可能有助于早期发现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44d4/6443556/5f8c8c4dcd05/1349-7235-58-0693-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验